Measles, mumps and rubella vaccine as an intralesional immunotherapy in treatment of warts

Aarti N. Shah; Dhara Patel; Vaaruni Ravishankar

doi:10.18203/2320-6012.ijrms20160298

Authors

Aarti N. Shah Department of Dermatology, NHL Municipal Medical College, Ahmedabad, Gujarat
Dhara Patel Department of Dermatology, NHL Municipal Medical College, Ahmedabad, Gujarat
Vaaruni Ravishankar Department of Dermatology, NHL Municipal Medical College, Ahmedabad, Gujarat

DOI:

https://doi.org/10.18203/2320-6012.ijrms20160298

Keywords:

Warts, Measles, Mumps and Rubella vaccine, Intralesional immunotherapy, MMR

Abstract

Background: To observe the efficacy and safety of intralesional Measles Mumps and Rubella (MMR) vaccine in the treatment of warts.

Methods: 50 patients with single or multiple warts more than 06 months duration in all age groups were included in the study. The patients received intralesional MMR vaccine 0.5ml into a single wart or the largest wart in case of multiple lesions at interval of two weeks for three treatments. The response was evaluated as 0-49% as no response, 50-99% as partial response and 100% as complete response. Follow up was made every 02 weeks for 06 weeks and then monthly for 06 months to detect any recurrence.

Results: Complete response was seen in 36 (72%), partial response in 08 (16%) and no response in 06 (12%) patients. No recurrence was observed. Pain at the site of injection in 18 (36%) and flu like symptoms in 02 (04%) patients were observed.

Conclusions: Intralesional immunotherapy with MMR vaccine was found to be a simple, effective, and safe treatment for warts. This study proved to be cost effective as patients can be treated with just 03 doses of MMR vaccine given at the interval of two weeks.

Metrics

Metrics Loading ...

References

Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006;4:273-93.

Rivera A, Tyring SK. Therapy of cutaneous human papillomavirus infections. Dermatol Ther. 2004;17:441-8.

Lichon V, Khachemoune A. Plantar warts: a focus on treatment modalities. Dermatol Nurs. 2007;19:372-5.

Dasher DA, Burkhart CN, Morrell DS. Immunotherapy for childhood warts. Pediatr Ann. 2009;38:373-9.

Murphy FA, Kingsbury DW. Virus taxonomy. In:Fields BN, Knipe DM, editors. Virology. New York: Raven Academic Press. 1990:9-35.

Nebesio CL, Mirowski GW, Chuang TY. HPV: Clinical significance and malignant potential. Int J Dermatol. 2001;40:373-9.

Lowry DR, Androphy EJ. Warts. In: Fitzpatrick’s dermatology in general medicine. IM Freedberg, AZ Eisen, W Klaus, KF Austen, LA Goldsmith, SI Katz (eds). Published by: McGraw-Hill Inc. New York. 2003;2:2119-31.

Kuykendall-Ivy TD, Johnson SM. Evidence-based review of management of nongenital cutaneous warts. Cutis. 2003;71:213-22.

Gamil H, Elgharib I, Nofal A, Abd-Elaziz T. Intralesional immunotherapy of plantar warts: Report of a new antigen combination. J Am Acad Dermatol. 2010;63:40-3.

Kilkenny M, Marks R. The descriptive epidemiology of warts in the community. Australas J Dermatol. 1996;37:80-6.

Laimins LA. The biology of human papillomavirus: From warts to cancer. Infect Agents Dis. 1993;2:74-86.

Bolton RA. Nongenital warts: Classification and treatment options. Am Fam Physician. 1991;43:2049-56.

Sterling JC, Handfield-Jones S, Hudson PM. British Association of Dermatologists.Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144:4-11.

Sterling JC. Virus infections. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. 7th ed. Oxford: Blackwell Science. 2004:25.15-25.37.

Center of Disease Control and Prevention. Sexually transmilted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002;51:1-78.

Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005;72: 647-52.

Kus S, Ergun T, Gun D, Akin O. Intralesional tuberculin for treatment of refractory warts. J Eur Acad Dermatol Venereol. 2005;19:515-6.

Clifton MM, Johnson SM, Roberson PK. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20:268-71.

King M, Johnson SM, Horn TD. Intralesional immunotherapy for genital warts. Arch Dermatol 2005;141:1606-7.

Signore RJ. Candida albicans intralesional injection immunotherapy of warts. Cutis. 2002;70:185-92.

Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida and trichophyton skin test antigens: a single-blinded, randomized and controlled trial. Arch Dermatol. 2005;141:589-94.

Johnson SM, Horn TD. Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol. 2004;3:263–65.

Phillips RC, Ruhl TS, Pfenniger JL, Garber MR. Treatment of warts with Candida antigen injection. Arch Dermatol. 2000;136:1274-5.

Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137:451-5.

Brunk D. Injection of Candida antigen works on warts. Skin Allergy News. 1999;30:5.

Gupta S, Malhotra AK, Verma KK, Sharma VK. Intralesional immunotherapy with killed Mycobacterium w vaccine for the treatment of ano-genital warts: an open label pilot study. J Eur Acad Dermatol Venereol. 2008;22:1089-93.

Maronn M, Salm C, Lyon V, Galbraith S. One-year experience with Candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol. 2008;25:189-92.